WO 2012/096245 A 1
Contents
1. 0029 sCD14 ST2. 75 1 000 30 5 0 2002 SCCM ES 1CM 1SF Internat ion al Sepsis Forum 5 2 5 Surviving Sepsis Campaign SSC Surv iv in g Sepsis Campaign guidelines SSCG 2004 2008 Crit Care Med 200 8 3 6 29
3. 2 4 4 8 7 2 1
4. ry 1 Etty re re r amp 15 0 SA THEAE EROS ORB i sa JP 1 oo 8g1t5 4 os 3 5 8 1 1101 AR 3252 2 pc sA 2 1o 2 2oo9 7 PCT JP2012 Z050226 Pic aa JP 201
5. ICU 7 2 2 KE RRB ST CIM eA
6. Blo BMH FHI S IRS RE FDA
7. Y CD 1 4 1 12 2005 Vol 9 No 1 Page 46 50 Y wo 2009 142303 Al 2009 11 26 1 12 0 0 13 00 3 3 amp US 2011 008638 1 Al amp EP 2280279 AI amp CA 2725 144 A amp CN 102037359 A MV c ra Ti BREHM re XK L
8. WO 2012 096245 7 PCT JP2012 050226 0017 BRC CHASUCFRICADET TSA RERED LNT CE MARRATE TOFRORA FETERE WO UO FECTAISSCON CER GE DS ABET HISS TEA ARHAGH OANA PeT ADET BIE AHA Y Nd BE Sea EH RUE SOUS 14 6 RSPAS UR Ns CD14_ STIERKA 0 PANPE FENIR ERI ITTE v s CD 14 ST 17 7 5 1 2pg mL I 524 927pg mL m 950 18 10pg mL lll 1858pg mL v TA Eh BUTEA SOUS 14 6 RPS Ua Ns CD 14 _ STESS 0 PANPE FENRIR ERI ITTE 920ng mL MEK JERNE e aR HENNA eS Ban SBE b Ft CHO BS 2 SRM Loa WY PCT BORER 0 0 Fe 1 86ng mL MEAK JERNE eaa Be METH FES EAR SEER DEF CHO BUTEA SOUS 14 6 RSPAS Uo Ns CD 14 _ ST PCT 3 0 PAPIYE TARO CANT ERAT OTHERS IFT Ce Eb BUTEA SOUS 1464 RR 8 24 B OFF 72 CH RRR SEMI DY MD sCD14_ STIEN LARK 0
9. WO 2012 096245 11 PCT JP2012 050226 0026 WRAAE ORI E LTI RHENOAHE SE 0027 a sCD14 _ ST b sCD14 ST c 0028 sCD14_ST Fab Fab F ab Fv
10. sCD14 ST Si MAL 2 sCD14 ST To sCD14 _ST a VEE 51858 pg mL 3 5 sCD14 ST sCD 14 _ ST CHW sC D14 _ ST OA PRB Cox sCD14 _ ST
11. sCD14_ ST 1 1 sCD14 ST 1 2 2 2 4 sCD14_ST sCD14 _ ST PCT
12. 4 040666 sCD14_STO 2 16 4 040666 S6 8 S68 F 1146 17 2 CD 14 F1031 8 3 F1106 13 3 E IA 4 040666 7 1 sCD14_ST PATHFAST sCD14_ST Gast em t WO 2012 096245 9 PCT JP2012 050226 0021 0022 Hm
13. Am J Infect Control 1988 16 12 8 140 001 3 1 WO 2012 096245 5 PCT JP2012 050226 0014 lt 90mmHg BEKO MODS D 1C ARDS ate AK 1 MODS S I RS
14. CD ROM WO 2012 096245 12 PCT JP2012 050226 0030 0031 0032 sCD14_ ST Bi 1
15. sCD 1 4 ST sCD14 ST 9 sCD14 ST 8 10 sCD14 ST 8 DAK 11 sCD14_ST 1 1 0 12 a sCD 14 _ ST b sCD14 ST c zzu Ev h 0009 sCD14_ST 4 040666 1 CD 14 1 3 WO 2012 096245 4 PCT JP2012 050226 CD14 1 S DS _ PAGE
16. 72 sCD14 ST 1 sCD14 ST 2 72 sCD14 ST 1 3 1 WO 2012 096245 3 PCT JP2012 050226 4 sCD14 ST 5 7 2 sCD14 ST 4 6 sCD14 ST 4 OW 7 4 8
17. Bo sCD14 _ STRE ORE 4 4 ROC rece iver operat ing character istic 1108pg mL 78 6 6 sCD14_ ST WO 2012 096245 10 PCT JP2012 050226 0023 0024 0025
18. A L P sCD14 ST 2 ALP sCD14 ST 2 sCD14_ST 14 6 s CD14_ST 3 0 1 sCD 14 ST 1 1 ER WO 2012 096245 14 PCT JP2012 050226 0035 sCD14 ST 4 77 512pg mL 1 I 524 927pg mL O 950 1810Opg mL Ui 1858pg mL wH 1858pg mL sCD14_ST IV 3 5 II IV P lt 0 0005 SCD14 S
19. FR GOK 5 FDA 1 4 040666 2 2005_ 106694 WO 2012 096245 2 PCT JP2012 050226 0005 0006 0007 0008 1 J Infect Chemother 2005 11 2 34 238 2 Med ica Postgraduates 2010 4 8 25 27 3 T he rapeut ic Reserach 2004 25 1689 1694 4 1CU CCV 2005 29 2 1 26 5 Am J Respir Crit Care Med 20 0 1 164 396 402
20. 1 sCD14 _ ST 7 2 sCD14 ST 4 sCD14 ST 4 4 sCD 14 _ ST sCD14 ST sCD14 ST 8 sCD14 ST 8 sCD14 ST 1 1 0
21. MARY 5CD14_ST 6 8 PC T 3 2 s CD 14 _ ST 1 PCT Kryptor automated analy zer BRAHMS 5 s CD14 ST 6 PCT A UC a 2 4 A UC b 7 2 A UC c s CD14 ST 7 2 3 0 6 PCT sCD14 ST 2 5 6 8 SCD14 ST PCT 3 0 1CU ROC sC D14_ST 1 PCT Krypt
22. 14 6 2 sCD14 ST PCT 3 0 ROC sCD14 ST 1 PCT Kryptor automat WO 2012 096245 15 PCT JP2012 050226 0038 0039 0040 ed analyzer BRAHMS o 4 100 sCD14 ST AUC 0 779 PCT AUC 0 52 1 CH PC T F D A sCD14 ST 5 7 2 PC T sCD14_ST 2 4 7 2 Cm sCD14 ST PCT 3 0 ROC
23. 18 4 2 1 gt 3 8 lt 3 6 2 gt 9 0 3 gt 20 PaC0 2 gt 4 3 kPa 4 gt 12000 lt 4000 ms gt 10 S RS sCD14_ST 24 7 2 EDTA 7 0 6 Acute Physiology And Chronic Health Score I APACHE 1 Glasgow Coma Scale GCS Sepsi WO 2012 096245 13 PCT JP2012 050226 0033 0034 s related Organ Failure Assessment Score SOFA Mortality in Emerge ney Depar
24. a sCD 14 _ ST WO 2012 096245 18 PCT JP2012 050226 b sCD14_ ST c 1 3 WO 2012 096245 PCT JP2012 050226 1 2 96 100 1 FTTT EE Tanna i il _ 80 HN 60 40 20 0 10 20 30 0 10 20 30 2 3 WO 2012 096245 PCT JP2012 050226 3 100 i 80 g 60 te 40 20 ol 0 10 20 30 4 sCD14 ST AUC 0 779 Cutoff 1108 pg mL P lt 0 001 PA aa sia i AUC 0 521 0 20 40 60 80 100 100 3 3 WO 2012 096245 PCT JP2012 050226 5 100 80 f 60 sobi 20 6 100 80 H jc 60 40 20 100 INTERNATIONAL SEARCH REPORT International application No PCT JP2 012 050226 A CLASSIFICATION OF SUBJECT MATTER G01N33 53 2006 01 4 According to International Patent Classification IPC or to both national classification and IPC FIELDS SEARCHED Minimum documentation searched classification system followed by classification symbols GO1N3 3 53 Documen
25. I NILA A M 6PANUTH Eberhard DE DE 2 6 6 9 2 2 1 2 Heidelberg DE 21 3 VANDIC Boris DE DE K 16 8 16 7 9 RT EE 5 2 a Muenchen DE 6HIRAKAWA Ka 54 Tite METHOD FOR PREDICTION OF PROGNOSIS OF SEPSIS 54 57 Abstract Disclosed is a method ior predicting the prognosis of sepsis characterized by measuring sCD14 ST in a sample sCD14 ST which is a substance to be measured in the present invention is a superior marker than procalcitonin which is a known marker for the prediction of prognosis in a sepsis patient 67 BMHFOsCD14 ST AHEFSGCCERMAECIFT SD MOENDFROFHFKReEART s CD 14 ST gt WO 2012 096245 1 PCT JP2012 050226 0001 0002 0003 0004
26. g ROC PERC es CN TST CHO WO 2012 096245 8 PCT JP2012 050226 001 8 001 9 0020 6 5 a 24 b 7 2 RRB cH PCT 3 0 ROC SCD14 ST sCD14_ST RNA
27. 0 520996 A be 2010 06 17 amp EP 2060920 A1 amp EP 2118665 A amp wo 2008 109903 Al amp AT 504943 A amp CA 2680537 A amp CN 101632022 A amp RU 2009 137583 A amp AT 504943 Al JP 2008 525 110A 2008 07 17 amp JP 2007 5 18062 A amp US 2005 0 148029 Al amp US 2005 0164238 Al amp US 2008 0050832 Al amp US 2009 0004755 Al amp US 2010 0240078 Al amp EP 1836493 A amp EP 1673465 A amp EP 2167962 A amp wo 2006 07 1583 A2 amp wo 2005 033327 A2 amp wo 2009 006347 A2 amp CA 2537668 A PCT 1SA 2 10 2 2009 7
28. 13 2kDa 2 N 1 3 2 16 sCD14_ ST s CD 14 _ ST 001 0 1 Thr Thr Pro Glu Pro Cys Glu Leu Asp Asp Glu 1 5 10 2 Arg VaL Asp ALa Asp ALa Asp Pro Arg GLn Tyr ALa Asp Thr VaL Lys 1 5 10 15 001 1 S IRS 4 2 Chest 1992 10 1 6 1644 1655 1 gt 3 8 lt 3 6 2 gt 9 0 3 gt 2 0 PaC0 gt 32torr 4 gt 12000 lt 4000 3 gt 10 001 2 PCR RP PC R
29. 6 327 BERHECHWT early goal directed therap y New Engl J Med 200 WO 2012 096245 6 PCT JP2012 050226 001 5 001 6 1 345 1368 1377 CHF CHDF HD PMX Crit Care Med 2008 3 6 296 327 200 61 20086 1C U
30. T 0036 3 PCT sCD14 _ ST 14 6 2 LEMRRHAOSCD14 STIB PCTHETNHETHICAM 3 0 2 sCD14 ST 3 PCT ER Fo sCD14 _ ST 1 PCT K ryptor automated analyzer BRAHMS sCD14 ST 920ng mL R PCT 1 86ng mL MIE A a SCD 14 ST PC 0037 4 PCT sCD14 ST ROC
31. W 2012 096245 AL ji RAR 12 19 Ae AQUA AUTO AA A A AA TTT 10 2012 19 9 07 2012 W O 2012 096245 A1 0 w OPCT 6 mon JP JP T 1608 15 GOIN 33 53 2006 01 7 Tokyo JP gry J ENDO Shigeatsu JP JP T 020001 1 21 PCT JP20 12 050226 4 2 5 5 wate JP 22 2012 i A 10 10 01 2012 REA CRE 25 T 1730004 6 7 8 26 5 Tokyo JP 81 BEB B AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO 30 201 1 003016 201 1 1 11 11 01 201 1 JP 71 CR CU CZ DE DK DM DO DZ EC EE EG ES Fl Mitsubishi Chemical GB GD GE GH GM GT HN HR HU ID IL IN IS Medienc
32. e Corporation JP JP T 1088559 JP KE Ieee KN KO KE LAs Gy ER CR ES 2 8 Tokyo WP PMS nM ME MO MS MN AWK MX MOCHIDA PHARMACEUTICAL CO LTD Mo Mes NAS NG NL NO NSS TOM PES POr RH Fla PT 7 QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ vc VN ZA ZM ZW JP JP T 1608515 Tokyo JP 72 75 B MATSUYA Takeshi JP JP T 1088559 84 BEB BE ARIPO BW GH GM KE LR LS MW gt Mz NA RW SD SL SZ TZ UG ZM ZW 2 8 are is Tokyo P OKAMURA Yoshikazu JP JP T 1088559 YA Al AT BE BG GH CY CZ DE DIG EE 2 8 ES Fl FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Tokyo JP xX THOMAE Ralf DE DE 12 8213 OAPI BF BJ CF CG Cl CM GA GN GQ GW ML MR NE SN TD TG 1 Gauting DE
33. or automated analyzer BRAHMS Kt WO 2012 096245 16 PCT JP2012 050226 0041 0042 ROC AUC 1 sCD1 4 _ ST PCT 1 WO 2012 096245 17 PCT JP2012 050226 1 2 3 4 5 6 7 8 9 10 11 12 sCD14 ST 72 SCD14_ST 1
34. s Relevant to claim No Y JP 2010 520996 A Biomedi ca Medi zinprodukte 1 12 GmbH amp Co KG 17 June 2010 17 06 2010 ent ire text pat icul ary claims amp EP 2060920 Al amp EP 2118665 A amp WO 2008 109903 Al amp AT 504943 A amp CA 2680537 A amp CN 101632022 A amp RU 2009137583 A amp AT 504943 Al X JP 2008 525110 A Biosite Inc 1 12 17 July 2008 17 07 2008 ent ire text pat icul ary claims JP 2007 518062 A US 2005 0148029 Al US 2005 0164238 Al US 2008 0050832 Al US 2009 0004755 Al US 2010 0240078 Al EP 1836493 A EP 1673465 A EP 2167962 A Wo 2006 071583 A2 Wo 2005 033327 A2 Wo 2009 006347 A2 CA 2537668 A Form PCT ISA 2 10 continuation of second sheet July 2009 pcT JP2012 050226 A ipc Int Cl GO1N33 53 2006 01 i B Int Cl GO1N33 53 JSTPlus JMEDPlus JST7580 JDreamll C
35. tation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922 1 996 Jitsuyo Shinan Toroku Koho 1996 2012 Kokai Jitsuyo Shinan Koho 1971 2012 Toroku Jitsuyo Shinan Koho 1994 2012 Electronic data base consulted during the international search name of data base and where practicable search terms used JST Plus JME DPlu s JST7580 JDreaml c DOCUMENTS CONSIDERED TOBERELEVANT CONSIDERED TO BE RELEVANT Category Citation of document with indication where appropriate of the relevant passages Relevant to claim No Shi geat su ENDO et al Us eful ness of Solubl 1 12 CD 14 Subtype Whi ch as ls a New Di agno stic Marke r for Seps is Japan Journal of Cri ti cal Care for Endotoxemi a 2005 vol 9 no 1 page s 46 to 50 wo 2009 142303 Al Mochi da Pharmaceut i cal Co 1 12 Ltd 26 November 2009 26 2009 ent ire text part icul a Claims paragraph 0013 0033 amp US 2011 0086381 Al amp EP 2280279 Al amp CA 2725144 A amp CN 102037359 A Further documents are listed in the continuation of Box C See patent family annex Special categories of cited documents T later document published after the international filing date or priority document defining the general state of the art which isnot considered date and not in conflict with the application but cited to understand to be of particular relevance the principle or theory
36. tment Sepsis MEDS 3 0 ICU GA Bit 3 0 3 0 1 sCD14_ST sCD14 ST 4040666 7 1 ALP S 6 8 NSR F 103 1_ 8 3 PATHFAST ALP S 6 8 S 68 Fa b ALP CDP st ar
37. underlying tiie invention earlier application or patent but published on or after the international bi document of particular relevance the claimed invention cannot be filing date considered novel or cannot be considered to involve an inventive document which may throw doubts on priority claim s or which is step when the document istaken alone cited to establish the publication date of another citation or other P document of particular relevance the claimed invention cannot be special reason as specified considered to involve an inventive step when the document is document referring to an oral disclosure use exhibnion or other means combined with one or more other such documents such combination document published prior to the international filing date but later than being obvious to aperson skilled in the art the priority date claimed document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 15 March 2012 15 03 12 27 March 2012 27 03 12 Name and mailing address of the ISA Authorized officer Japane se Patent Office Facsimile No Telephone No Form PCT ISA 210 second sheet July 2009 International application No PCT JP2 012 050226 INTERNATIONAL SEARCH REPORT C Continuation DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document with indication where appropriate of the relevant passage
Download Pdf Manuals
Related Search